Executive Committee

Jane Anderson, MSN, Ph.D.

Jane Anderson is Associate Chief of Nursing Research, Michael E DeBakey VA Medical Center; Assistant Professor, Department of Neurology, Baylor College of Medicine; and a nurse scientist with the Houston HSR&D Center for Innovations in Quality, Effectiveness and Safety (IQuEST) where she has developed a program of research to identify effective health information technology, telehealth modalities and implementation strategies for stroke care and prevention. Her projects include development and implementation of a telehealth self-management support program for stroke risk reduction, decision support tools for evidence-based stroke care, and a valid and reliable nurse-administered swallowing screening tool for patients with stroke. Anderson has expanded the program of research, developed in the VA, to the State of Texas through collaboration with the Lone Star Stroke (LSS) Consortium. In February 2018, she was named Principal Investigator for LSS studies at BCM.


Carleigh Baudoin, MPH

Ms. Baudoin holds a Bachelor of Arts degree in anthropology from Louisiana State University and a Master of Public Health degree from Tulane University School of Public Health and Tropical Medicine. She has over six years of public health experience and currently serves as Manager of the Chronic Disease Branch at the Department of State Health Services.  In this role, she oversees the Texas Heart Attack and Stroke Data Collection Initiative.  In addition to this project, Ms. Baudoin manages six other chronic disease-related programs that emphasize community health and health systems improvement.


Robin L. Brey, M.D.

Robin L. Brey, M.D.

Dr. Brey is Professor and Chair of the Department of Neurology, and Edna Smith Dielmann Distinguished University Chair at the University of Texas Health Science Center at San Antonio (UTHSCSA). She was instrumental in creating a Joint Commission-certified Primary Stroke Center at University Hospital, San Antonio, TX. Her research interests include the study of the relationship between antiphospholipid antibodies and stroke as well as neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE). Dr. Brey has participated in 3 expert panels on antiphospholipid antibodies (aPL) to help establish the appropriate criteria for clinical and laboratory diagnosis of the aPL Syndrome for research purposes. Dr. Brey has been the Principal Investigator on grants from the NIH and the American Heart Association. Formerly a member of the American Academy of Neurology (AAN) Board of Directors, Dr. Brey currently serves as the Editor-in-Chief of Neurology Now, the AAN publication for neurology patients, their families and the lay public.



Salvador Cruz-Flores, M.D., M.P.H.

Dr. Cruz-Flores is Professor and Chair of Neurology at Texas Tech University Health Sciences Center-El Paso. He attended medical school at the Universidad Autonoma de Nuevo Leon in Monterrey, Mexico and trained in Internal Medicine and Neurology at the Universidad Autonoma de Nuevo Leon. Dr. Cruz-Flores completed a neurology residency and a two-year fellowship in cerebrovascular diseases and neurocritical care at Saint Louis University. He also obtained a Masters degree in Public Health (Epidemiology) from Saint Louis University School of Public Health. Dr. Cruz-Flores is board certified in Neurology, Vascular Neurology, Neuro-Imaging, and Neuro-Critical Care.


Mark Goldberg, M.D.

Mark Goldberg, M.D.

Dr. Goldberg is Professor of Neurology and Neurotherapeutics at UT Southwestern Medical Center in Dallas. Previously, Dr. Goldberg was professor of neurology and founding director of the Hope Center for Neurological Disorders at Washington University in St. Louis. He earned his medical degree from Columbia University after graduating from Harvard University with a bachelor’s degree in biology. He completed his neurology residency at Stanford University, where he also was a postdoctoral research fellow. Dr. Goldberg is board certified in neurology and vascular neurology. His research interests are in white matter injury and mechanisms of recovery after stroke. Under his leadership, UT Southwestern is undergoing rapid growth in clinical and translational neuroscience, with state-of-the-art facilities for drug and device testing, and new initiatives to support collaborative research on brain disease therapy.


James Grotta, M.D.

James Grotta, M.D.

Dr. Grotta is former Professor and Chairman of the Department of Neurology at the University of Texas Medical School at Houston.  Dr. Grotta first joined the University of Texas – Houston Medical School faculty in 1979. His research focuses on the development of new therapies for acute stroke patients. He has been funded by the NIH for translational research from the laboratory to bedside and has been a leader of many clinical research studies of both thrombolytic drugs and cytoprotective agents after stroke. Dr. Grotta has built a collaborative network between the UT Stroke Team, Memorial Hermann Hospital, Houston Fire Department-Emergency Medical Services, and other regional stroke centers to increase the delivery of appropriate therapy to acute stroke patients in Houston, one of the first such networks in the country. In 2014, he moved his practice to Memorial Hermann Hospital to put into operation and evaluate the first Mobile Stroke Unit in the U.S. — an ambulance equipped with a CT scanner and staffed by Dr Grotta or another Vascular Neurologist, nurse, paramedic and CT tech to take emergency department evaluation and treatment directly to the acute stroke patient.  Dr. Grotta received the Feinberg Award for Excellence in Clinical Stroke from the American Heart Association (AHA) in 1999, the AHA Physician of the Year Award for 2006, the Eugene Braunwald Award for Mentoring in 2010, and awards for teaching excellence at UT Medical School for 14 years. He has authored or co-authored more than 300 articles in peer-reviewed journals.


Thomas A. Kent, M.D.

 Dr. Thomas Kent is the Robert A. Welch Professor and Associate Dean of Education for the Engineering Medicine School (EnMed) of the Texas A&M University Health Science Center-Houston campus. He is also a member of the Institute of Biosciences and Technology at the Texas Medical Center. Dr. Kent is Adjunct Professor in the Texas A&M College of Engineering, College Station, TX, and in the Department of Chemistry at Rice University, Houston, Texas.  Prior to joining Texas A&M, Dr. Kent was Professor and Director of Stroke Research and Education in the Department of Neurology at the Baylor College of Medicine in Houston, Texas. Dr. Kent is a Fellow of the American Heart Association and has been a member and or/Chair of several AHA and NIH grant review committees. His clinical work is recognized as a Castle Connolly Top Doctor in America, Texas Monthly Superdoctor© and “Best of the Best” physicians by the Houston Chronicle. His active research program spans development of nano-medicine approaches to treat ischemia/reperfusion injury, clinical trials of stroke prevention, and new analytical methodologies for ischemic and hemorrhagic stroke trials. He has a special interest in diabetes and stroke and its role in the poor outcomes seen especially in minority populations.


BethLynn Maxwell, Ph.D., J.D.

Dr. Maxwell is Chief Health Research Officer in the Office of Health Affairs and Associate General Counsel – Legal Expert in the Office of General Counsel at The University of Texas System. Her main responsibility is to develop, manage, implement and evaluate several new UT System health initiatives (e.g., clinical trials collaborations, collaboration among the CTSA programs at 5 UT System health institution, biobank consortium, etc.). Additionally, Dr. Maxwell supports the UT System health institutions in developing, implementing, and overseeing research policies and procedures. Dr. Maxwell joined the Office of General Counsel in 1997 as a patent attorney. Before joining UT, Dr. Maxwell was a patent attorney with Fish & Richardson P.C. in Houston, TX. Previously, she oversaw and managed a tissue culture core research laboratory and performed research in the Department of Cell Biology, Baylor College of Medicine, Houston, TX.  She received a Ph.D. and M.S. in Molecular Biology from The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences and a J.D. from South Texas College of Law.



Sean I. Savitz, M.D.

Dr. Savitz is a tenured Professor of Neurology, holds the Frank M. Yatsu Chair in Neurology, and directs the Stroke Program at the University of Texas Medical School in Houston.  He graduated from Harvard College, received his MD from Albert Einstein College of Medicine, and completed neurology residency training and a cerebrovascular fellowship at the Harvard Medical School Neurology Training Program.  He and his team run one of the largest academic stroke programs in the world, testing novel treatments for patients with ischemic stroke and brain hemorrhage.  Dr. Savitz oversees a bidirectional, translational laboratory and clinical research program on cell therapies in stroke and is conducting some of the first clinical trials testing cell therapies in stroke patients.  He also oversees a fellowship program to train stroke specialists and has won several teaching awards both in Boston and at UTHealth.  He has been funded by grants from the National Institute of Health, the Howard Hughes Medical Institute, and the American Heart Association, and is an author of over 100 publications in the biomedical literature.



Steven Warach, M.D., Ph.D.

Dr. Warach graduated from Michigan State University with a doctorate in neuroscience and psychology. He received his medical degree and neurology residency training at Harvard Medical School, before joining the Harvard Medical School faculty in 1993, as Chief of the Division of Cerebrovascular Diseases at Beth Israel Hospital. In 1999, he was recruited by the National Institutes of Neurological Disorders and Stroke as Senior Investigator and Chief of the Section of Stroke Diagnostics and Therapeutics, a translational clinical research program in acute stroke that established the first stroke centers in Washington DC and Suburban Maryland. In 2011, he was recruited by University of Texas Southwestern Medical Center and the Seton Healthcare Family to serve as Professor and founding Executive Director of the Seton/UT Southwestern Clinical Research Institute of Austin. Dr. Warach’s research is internationally recognized as introducing advanced MRI methods for more accurate diagnosis of stroke into clinical practice and for pioneering patient-specific, imaging-defined therapeutic targets in the development of new stroke therapies.


Mireya Zapata

Mireya Zapata applies her diverse leadership experiences in government, marketing, communications, and nonprofits as Executive Vice President of the Lumbermen’s Association of Texas, the leading trade association for independent businessmen and women who own retail lumber and building material companies. A seasoned government affairs professional, Mireya represents LAT at the Texas legislature and in Washington DC. Prior to LAT, Mireya led government affairs and board leadership for the National Multiple Sclerosis Society in a five-state region. Her work in health care public policy began at the Texas House of Representatives where she worked for two Chairmen of the House Human Services Committee including eight years as Chief of Staff. In 2016, Mireya’s husband Bob Ferman suffered a stroke at the age of 40. This life-changing experience sparked her passion for stroke research and led to her volunteer advocacy on behalf of the Lone Star Stroke Consortium during the 2017 session of the Texas Legislature.